Black Diamond Therapeutics Inc logo

BDTX - Black Diamond Therapeutics Inc News Story

$26.29 0.2  0.7%

Last Trade - 22/04/21

Sector
Healthcare
Size
Mid Cap
Market Cap £686.7m
Enterprise Value £458.9m
Revenue £n/a
Position in Universe 2874th / 6857

Black Diamond Therapeutics Announces the Appointment of Biopharmaceutical Veteran Robert A. Ingram as Chairman of the Board

Tue 29th September, 2020 12:45pm
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20200929:nGNX3lTNF0


CAMBRIDGE, Mass. and NEW YORK, Sept. 29, 2020 (GLOBE NEWSWIRE) -- Black
Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine
company pioneering the discovery and development of small molecule,
tumor-agnostic therapies, today announced the appointment of Robert A. Ingram
as the Chairman of its Board of Directors. Brad Bolzon, Ph.D., Chairman and
Managing Director at Versant Ventures and Black Diamond’s founding Chairman,
will remain on the Company’s board.

“As we welcome Bob to his new role, I would like to thank Brad for the
integral role he played as Chairman of the Board of Black Diamond from our
founding with Versant through our transition to a public company, and I’m
very happy that he will continue to help guide the company as a director,”
said David M. Epstein, Ph.D., President and Chief Executive Officer of Black
Diamond Therapeutics. “Bob is a world-class leader in the pharmaceutical
industry having guided and shaped numerous companies including serving as CEO
and Chairman of GlaxoWellcome and his role in the merger that formed
GlaxoSmithKline. His leadership and expertise will be critical as we continue
to execute on our strategy to become a leading precision oncology company.”

“Black Diamond possesses an innovative and proprietary MAP platform,
compelling clinical and early stage assets, and dynamic leadership team, and
has the potential to transform the oncology therapeutic landscape,” said Mr.
Ingram. “I’m thrilled to join as Chairman to help Black Diamond achieve
its vision of developing precision oncology medicines for all patients with
genetically defined cancers.”

“It’s my pleasure to welcome Bob to the Board of Black Diamond,” said
Dr. Bolzon. “He is the ideal fit for the company’s next stage of growth,
given his deep experience leading both biotech and pharma companies.”

Mr. Ingram served as Chief Executive Officer and Chairman of GlaxoWellcome,
where he co-led the merger and integration that formed GlaxoSmithKline (GSK).
Mr. Ingram is currently a General Partner at Hatteras Venture Partners, a
venture capital firm that invests in early stage life sciences companies. He
also serves as Chairman of the Board of BioCryst Pharmaceuticals, Inc., and is
a board member of Novan, Inc., and of HBM Healthcare Investments. The
recipient of three presidential appointments, Mr. Ingram was the Founding
Chair of the CEO Roundtable on Cancer and currently serves as a member of the
President’s Cancer Panel. He also serves on the board of the Research
Triangle Foundation of North Carolina, the Research Triangle Institute, and is
Chairman of the GSK Foundation. In 2013, Mr. Ingram received the NACD B.
Kenneth West Lifetime Achievement Award from the National Association of
Corporate Directors. He obtained his B.S. in Business Administration from
Eastern Illinois University.

About Black Diamond

Black Diamond Therapeutics is a precision oncology medicine company pioneering
the discovery of small molecule, tumor-agnostic therapies. Black Diamond
targets undrugged mutations in patients with genetically defined cancers.
Black Diamond is built upon a deep understanding of cancer genetics, protein
structure and function, and medicinal chemistry. The Company’s proprietary
technology platform, Mutation-Allostery-Pharmacology (MAP) platform, is
designed to allow Black Diamond to analyze population-level genetic sequencing
data to identify oncogenic mutations that promote cancer across tumor types,
group these mutations into families, and develop a single small molecule
therapy in a tumor-agnostic manner that targets a specific family of
mutations. Black Diamond was founded by David M. Epstein, Ph.D. and Elizabeth
Buck, Ph.D., and, beginning in 2017, together with Versant Ventures, began
building the MAP platform and chemistry discovery engine. For more
information, please visit www.blackdiamondtherapeutics.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not
historical facts are “forward-looking statements” within the meaning of
the Private Securities Litigation Reform Act of 1995. Because such statements
are subject to risks and uncertainties, actual results may differ materially
from those expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding future plans
or expectations for the Mutation-Allostery-Pharmacology platform, including
the potential of the Company’s strategy and product candidates, and the
continued development and advancement of the Company’s pipeline, including
BDTX-189 and early-stage pipeline programs. Any forward-looking statements in
this statement are based on management’s current expectations of future
events and are subject to a number of risks and uncertainties that could cause
actual results to differ materially and adversely from those set forth in or
implied by such forward-looking statements. Risks that contribute to the
uncertain nature of the forward-looking statements include: the success, cost,
and timing of the Company’s product candidate development activities and
planned clinical trials, the Company’s ability to execute on its strategy,
regulatory developments in the United States, the Company’s ability to fund
operations, and the impact that the current COVID-19 pandemic will have on the
Company’s clinical trials, supply chain, and operations, as well as those
risks and uncertainties set forth in its 2019 annual report on Form 10-K filed
with the United States Securities and Exchange Commission and its other
filings filed with the United States Securities and Exchange Commission. All
forward-looking statements contained in this press release speak only as of
the date on which they were made. The Company undertakes no obligation to
update such statements to reflect events that occur or circumstances that
exist after the date on which they were made.

Contacts:

For Investors:
Natalie Wildenradt
investors@bdtherapeutics.com

For Media:
Kathy Vincent
(310) 403-8951
media@bdtherapeutics.com


(https://www.globenewswire.com/NewsRoom/AttachmentNg/b8da4d92-789b-4f0a-a1e2-2739af370155)



GlobeNewswire, Inc. 2020
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.